PMVP logo

PMVP PMV Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$0.88
-0.43 (-33.13%)

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The …

Market Cap: $46.72Mwww.pmvpharma.com

Price

No data yet.

Social Signal Score

49
5d
50
1 mentions
—
30d
40
2 mentions
—
60d
53
4 mentions
—
90d
54
8 mentions
—
news: 8

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$5+470.8%
Low $5Median $5High $5
Current Consensus

Revenue

$0.00
$0.00
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.51
$-1.55–$-1.49
3 analysts
FY2026
$-1.32
$-1.48–$-1.19
3 analysts
FY2027
$-0.88
$-1.02–$-0.72
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David H. Mack
Sector
Healthcare
Industry
Biotechnology
Employees
54
Beta
1.35
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-7.19
www.pmvpharma.com